Report ID: SQMIG35A2547
mRNA Therapeutics Market Size, Share, Growth Analysis, By Type (Prophylactic Vaccines, Therapeutic Vaccines, Therapeutic Drugs), By Application (Rare Genetic Diseases, Oncology, Respiratory Diseases, Infectious Diseases), By Region - Industry Forecast 2024-2031
Report ID:
SQMIG35A2547 |
Region:
Global |
Published Date: February, 2024
Pages:
157
|
Tables:
65 |
Figures:
75
mRNA Therapeutics Market News
in mRNA Therapeutics Market
- Monkeypox may be rare, but it is a serious contagious disease that can be transferred from animals to humans. BioNTech and Pfizer developed a vaccine against the illness, the mRNA-BNTX162b2 vaccine. They turned in an IND (Investigational New Drug) application in April 2023 to the FDA for testing and approval.
- Moderna got the FDA’s greenlight for its mRNA-1273 vaccine in June 2023. At the same time, Pfizer was also granted approval for their BNT162b2 vaccine. These vaccines were designed against COVID-19 for children aged from six months to five years old
- Moderna gave the FDA an IND application in March 2023. This was in regard to their mRNA-1273 vaccine against respiratory syncytial virus (RSV). This vaccine has helped reduce the possibility of respiratory tract infection occurrence in young children and infants.
- CureVac turned in an IND application to the US Food and Drug Administration in May 2023. This was regarding their CV7201 vaccine against COVID-19. This disease is branched from the SARS-CoV-2 virus.
mRNA Therapeutics Market Report Snapshots
Want to customize this report?
Our industry expert will work with you to provide you with customized data in a short amount of time.
REQUEST FREE CUSTOMIZATION
USA (+1) 351-333-4748
